Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation

Canadian Journal of Cardiology

Volumn 29, Issue 9, 2013, Pages 1110-1117

  Chen, Huang Chung ^a   Chen, Yung Lung ^a   Guo, Bih Fang ^a   Tsai, Tzu Hsien ^a   Chang, Jen Ping ^a   Pan, Kuo Li ^b   Lin, Yu Sheng ^b   Chen, Mien Cheng ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; CARDIAC IMPLANTABLE ELECTRONIC DEVICE; CHINESE; DISEASE SEVERITY; DRUG WITHDRAWAL; HEART ASSIST DEVICE; HEART RHYTHM; HEMATOMA; INCIDENCE; POCKET HEMATOMA; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOCYTOPENIA;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ASPIRIN; CHINA; CROSS-SECTIONAL STUDIES; DEFIBRILLATORS, IMPLANTABLE; DRUG THERAPY, COMBINATION; FEMALE; HEMATOMA; HEPARIN; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOCYTOPENIA; TICLOPIDINE; WARFARIN;

EID: 84882829044     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.12.014     Document Type: Article

References (30)

1. Bernard M.L., Shotwell M., Nietert P.J., Gold M.R. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ Arrhythm Electrophysiol 2012, 5:468-474.
2. Wiegand U.K., LeJeune D., Boguschewski F., et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004, 126:1177-1186.
3. Lekkerkerker J.C., van Nieuwkoop C., Trines S.A., et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009, 95:715-720.
4. Romeyer-Bouchard C., Da Costa A., Dauphinot V., et al. Prevalence and risk factors related to infections of cardiac resynchronization therapy devices. Eur Heart J 2010, 31:203-210.
5. Douketis J.D., Spyropoulos A.C., Spencer F.A., et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012, 141(2 Suppl):e326S-e350S.
6. Cairns J.A., Connolly S., McMurtry S., Stephenson M., Talajic M. CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol 2011, 27:74-90.
7. Douketis J.D., Johnson J.A., Turpie A.G. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004, 164:1319-1326.
8. Pengo V., Cucchini U., Denas G., et al. Italian Federation of Centers for the Diagnosis of Thrombosis and Management of Antithrombotic Therapies (FCSA). Standardized low-molecular-weight heparin bridging regimen in outpatients on oral anticoagulants undergoing invasive procedure or surgery: an inception cohort management study. Circulation 2009, 119:2920-2927.
9. Kutinsky I.B., Jarandilla R., Jewett M., Haines D.E. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010, 3:312-318.
10. Tompkins C., Cheng A., Dalal D., et al. Dual antiplatelet therapy and heparin "bridging" significantly increase the risk of bleeding complications after pacemaker or implantable cardioverter-defibrillator device implantation. JAm Coll Cardiol 2010, 55:2376-2382.
11. Cano O., Osca J., Sancho-Tello M.J., Olagüe J., Castro J.E., Salvador A. Morbidity associated with three different antiplatelet regimens in patients undergoing implantation of cardiac rhythm management devices. Europace 2011, 13:395-401.
12. Cheng A., Nazarian S., Brinker J.A., et al. Continuation of warfarin during pacemaker or implantable cardioverter-defibrillator implantation: a randomized clinical trial. Heart Rhythm 2011, 8:536-540.
13. Giudici M.C., Paul D.L., Bontu P., Barold S.S. Pacemaker and implantable cardioverter defibrillator implantation without reversal of warfarin therapy. Pacing Clin Electrophysiol 2004, 27:358-360.
14. Jamula E., Douketis J.D., Schulman S. Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide. JThromb Haemost 2008, 6:1615-1621.
15. Ahmed I., Gertner E., Nelson W.B., et al. Continuing warfarin therapy is superior to interrupting warfarin with or without bridging anticoagulation therapy in patients undergoing pacemaker and defibrillator implantation. Heart Rhythm 2010, 7:745-749.
16. Abualsaud A.O., Eisenberg M.J. Perioperative management of patients with drug-eluting stents. JACC Cardiovasc Interv 2010, 3:131-142.
17. Sawada T., Shinke T., Shite J., et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011, 75:99-105.
18. Michaud G.F., Pelosi F., Noble M.D., Knight B.P., Morady F., Strickberger S.A. Arandomized trial comparing heparin initiation 6 h or 24 h after pacemaker or defibrillator implantation. JAm Coll Cardiol 2000, 35:1915-1918.
19. Cano O., Muñoz B., Tejada D., et al. Evaluation of a new standardized protocol for the perioperative management of chronically anticoagulated patients receiving implantable cardiac arrhythmia devices. Heart Rhythm 2012, 9:361-367.
20. Healey J.S., Eikelboom J., Douketis J., et al. Peri-procedural bleeding and thromboembolic events with dabigatran compared to warfarin: results from the RE-LY randomized trial. Circulation 2012, 126:343-348.
21. Boulé S., Marquié C., Vanesson-Bricout C., et al. Clopidogrel increases bleeding complications in patients undergoing heart rhythm device procedures. Pacing Clin Electrophysiol 2012, 35:605-611.
22. Hovens M.M., Snoep J.D., Eikenboom J.C., van der Bom J.G., Mertens B.J., Huisman M.V. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J 2007, 153:175-181.
23. Mason P.J., Jacobs A.K., Freedman J.E. Aspirin resistance and atherothrombotic disease. JAm Coll Cardiol 2005, 46:986-993.
24. Nguyen T.A., Diodati J.G., Pharand C. Resistance to clopidogrel: a review of the evidence. JAm Coll Cardiol 2005, 45:1157-1164.
25. Fujiwara T., Ikeda M., Esumi K., et al. Exploratory aspirin resistance trial in healthy Japanese volunteers (J-ART) using platelet aggregation as a measure of thrombogenicity. Pharmacogenomics J 2007, 7:395-403.
26. Li Q., Chen B.L., Ozdemir V., et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007, 8:577-586.
27. Hwang S.J., Jeong Y.H., Kim I.S., et al. The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thromb Res 2011, 127:23-28.
28. Verschuren J.J., Trompet S., Wessels J.A., et al. Asystematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?. Eur Heart J 2012, 33:165-175.
29. Page R.L., Lawrence J.D. Potentiation of warfarin by dong quai. Pharmacotherapy 1999, 19:870-876.
30. Samuels N. Herbal remedies and anticoagulant therapy. Thromb Haemost 2005, 93:3-7.